Rationale: Bronchial epithelium exposed to cigarette smoke undergoes a series of histological changes that may ultimately lead to invasive cancer. Inhaled corticosteroids reduce the number of lung tumors developing in rats exposed to cigarette smoke. Objectives: We studied the effect of inhaled fluticasone on premalignant lesions in smokers and patients curatively treated for head and neck cancer or lung cancer. Methods: Participants were screened for premalignant lesions by bronchoscopy. Biopsies were taken from three to five locations and classified using WHO criteria. In case of a metaplasia index of >15%, participants were randomized to receive a powder inhalation device containing either fluticasone 500 µg or a placebo, to be used twice a day. After 6 months, biopsies were obtained from the same locations as previously sampled. Efficacy of treatment was assessed by reversal of metaplasia/ dysplasia; secondary end-points were reversal of increased p53 and KI-67 immunoreactivity and hTERT expression. Measurements: Of the 201 subjects that were screened, 108 were included. Mean age was 53 years (35-71), mean number of pack-years 48 (18-99), mean metaplasia index 48% and 32% had some degree of dysplasia at baseline. Main results: The two treatment arms did not differ with respect to response or change in either metaplasia index or the expression of the markers p53, KI-67 or hTERT. Conclusion: inhaled Fluticasone in a dose of 2x500 µg does not affect the natural course of premalignant lesions in the central airways.
Introduction
Despite advances in treatment, lung cancer causes more deaths than any other malignancy 1 . Its main cause is tobacco smoking 2 , which is recognised as a danger to public health and targeted by anti-smoking campaigns and legislation that prohibits smoking in public spaces. However, even when antismoking measures reduce the number of smokers, lung cancer will remain an important cause of cancer mortality in the foreseeable future. The process of carcinogenesis takes many years and although the risk of lung cancer declines in the years after quitting, many former smokers develop lung cancer. A study by Tong et al. reported that 42% of 1039 lung cancer patients were former smokers 3 . Of the male patients 15% had stopped over 15 years before diagnosis. Successes in the preventive treatment of risk factors in cardiovascular medicine suggest that a similar course of action may be successful in the fight against lung cancer. Cancer chemoprevention is feasible in theory. Certain drugs or (dietary) supplements may counteract the effects of carcinogenic substances on healthy subjects at risk of developing cancer. Many mechanisms of carcinogenesis have been elucidated over the past decades and drugs affecting this process have proven their benefit in in-vitro and animal studies. In large clinical trials tamoxifen reduced the risk of recurrence of breast cancer 4 and as such is a proof of principle for cancer chemoprevention. Inhalational corticosteroids (ICS) are promising for lung cancer chemoprevention. Corticosteroids inhibit tumor growth in vitro 5 and both ingested and inhaled, this class of drugs reduces the number of lung tumors developing in rats exposed to cigarette smoke 6 and in a transgenic (p53/p16 null) mouse model treated with benzo-a-pyrene 7 . ICS have been used in the treatment of asthma for years and were proven safe in long term use, which is important if a substance is to be used for large scale chemoprevention.
Bronchial epithelium exposed to cigarette smoke will often undergo a sequence of histological changes, from hyperplasia through squamous metaplasia and different grades of dysplasia. These changes may eventually lead to invasive squamous cell carcinoma. This sequential morphological progression is thought to be driven by an accumulation of genetic and epigenetic changes. In this trial we examined the effect of fluticasone on premalignant epithelial lesions of the bronchus: reversal of histological abnormalities of the bronchial epithelium was the primary end point. As a secondary end-point we chose the expression of three biomarkers: P53, KI-67 and hTERT. These markers are indicative of changes on a molecular level and may add to the predictive value of histology [8] [9] [10] [11] . Some of the results of this study have been previously reported in the form of an abstract 12 .
Materials and methods

Subjects and screening
Volunteers with a smoking history of over 20 pack years (one pack of cigarettes a day for over 20 years or equivalent) were recruited by advertisements in local and national newspapers. Patients who had undergone treatment of head and neck-or lung cancer and did not show signs of recurrence were also asked to participate. Subjects with serious comorbid disease, FEV 1 values below 1000 ml or use of systemic corticosteroids in the year prior to enrollment were excluded. Women of childbearing potential could only participate if they agreed to undergo a pregnancy test and used an approved method of contraception for the duration of the study.
Participants were subsequently screened with bronchoscopy. Biopsies were taken from 3 to 5 locations. One biopsy per location was formalin fixed and paraffin embedded for immunohistochemistry and histological assessment on a series of haematoxylin and eosin (H&E) stained sections by a staff pathologist according to WHO guidelines. One other biopsy was snap frozen in liquid nitrogen. At least one biopsy was to contain squamous metaplasia or dysplasia for the subject to be included in the study. Protocols were approved by the institutional review boards and written informed consent was obtained from all subjects.
Randomization and treatment
A centralized trial service assigned subjects to a treatment or placebo arm by blocked stratified randomization. The institution where screening and follow up took place was used as stratification factor. Subjects received a powder inhalation device (diskus inhaler) containing sixty doses of either 500 μg fluticasone or a placebo to be used twice daily. All inhalers were kindly provided free of charge by GlaxoSmithKline. Each month, subjects received a new inhaler, inhalation technique was evaluated and compliance, smoking behavior and adverse events were monitored (NCI common toxicity criteria). After six months a second bronchoscopy was performed. Those who had used a placebo and had persistant bronchial premalignant lesions were offered treatment for another six months with fluticasone.
Evaluation of efficacy
Histology
The effect of fluticasone on the histology of bronchial biopsies was analysed by comparing the average change in metaplasia index (the number of squamous lesions divided by the number of locations biopsied) of two arms. Also a modified version of the method of Lam et al. 13 was used. See table 1.
Markers
HTERT: Twenty-five ten µm sections were cut from the snap-frozen biopsies and lysed in RNAzol Bee (Campro Scientific, the Netherlands). RNA was isolated according to the manufacturers instructions. Levels of hTERT mRNA expression were determined with a quantitative one step real-time reverse transcriptase PCR, using the lightcycler instrument and the lightcycler TeloTAGGG hTERT quantification kit (Roche, Germany) according to the manufacturers instructions. The housekeeping gene Porphobilinogen Deaminase was amplified and detected in the same reaction, serving as a reference as well as internal control for RNA quality. Experiments were performed in duplicate. Normalized mean hTERT level of two experiments was used for analysis.
Classification Definition
Lesion-specific
Complete response:
Regression of a metaplastic or dysplastic lesion to hyperplasia or normal.
Progressive disease:
Appearance of lesions classified as squamous metaplasia or worse, irrespective of whether the site was biopsied at baseline, or worsening of the metaplastic lesion present at baseline by two or more grades Regression of all metaplastic lesions found at baseline to lesions that were no worse than hyperplasia and the appearance of no new metaplastic lesions Partial response:
Regression of some but not all of the metaplastic lesions with the appearance of no new lesions that were squamous metaplasia or worse. Progressive disease:
Progression of one or more sites by two or more grades or the appearance of new metaplastic lesion.
Stable disease: Subjects who did not have a complete response, partial response, or progressive disease. 
Statistics
Power analysis indicated that inclusion of 90 subjects would give the study 80% statistical power to detect a difference of 30% in response rate (CR+PR; two tailed test, χ2= 0.05). The SAS version 9 program was used for statistical tests. Categorial variables were tested using Fisher exact test (location specific analysis) or Jonkheere Terpstra test when appropriate. Continuous variables were tested by t-tests. Logistic regression analysis was performed to adjust for sex, institution where screening and follow up took place, number of pack years and history of cancer. Mean metaplasia index at baseline was 47% (median 33%), 35% had some degree of dysplasia. Baseline characteristics were well balanced among the intervention and the placebo group, except for one: all subjects with a history of lung (1) or head and neck cancer (6) were allocated to the placebo group. In one subject assigned to the placebo group a carcinoid tumor was discovered at the time of the second bronchoscopy, another developed bronchioloalveolar carcinoma during the open label phase of the study (while on fluticasone). Both subjects who developed cancer are included in the analysis. Seventeen subjects failed to complete the trial according to protocol. One subject, allocated to the fluticasone arm of the study, underwent the second bronchoscopy one month earlier than planned because of side effects (recurrent stomatitis). This person had a complete response and was included in the analysis. Of the sixteen Table 2 Subject characteristics subjects who were not included in the analysis, 9 were in the placebo-and 7 in the fluticasone arm ( figure 1) . The average number of doses taken per month was 56 (20-60 median 57 SD 5.0), without any difference between subjects assigned to the fluticasone or placebo arm. Data from 92 subjects were available for analysis. Of the subjects allocated to the placebo arm, 21 were subsequently included in the crossover part of the trial. Adverse events related to toxicity of study medication were reported on 68 occasions and were limited to thrush, cough and hoarseness of the voice. All toxicity related adverse events were below CTC grade 3.
Histology
Lesion specific analysis
At baseline a total of 437 locations were biopsied. Of these locations 320 yielded biopsies of sufficient quality from subjects who finished the trial according to protocol. After 6 months 291 locations that were sampled at baseline were biopsied a second time. Fifty-three locations were sampled that were not biopsied at baseline. The complete response rate on a lesion level was 27% in the fluticasone group and 22% in the placebo group (p> 0.30 see table  3 ). The progressive disease rate was13% and 18% for fluticasone and placebo respectively. For analysis of the crossover part of the trial the response of 39 Table 3 Lesion-and subject specific analysis of histology locations (21 subjects) after using open-label fluticasone for 6 months was compared to the response of all locations in the placebo arm. Again, fluticasone did not influence the response (data not shown).
Subject specific analysis
Ninety-two subjects had results suitable for analysis. Complete response rate was 34% in the fluticasone group and 38% in the placebo group, progressive disease was found in 43% in the fluticasone and 38% in the placebo group (p=0.75 see table 3). Stratified analysis showed that institution, number of pack-years, sex and history of cancer, did not confound the main comparison. Before intervention mean metaplasia index was 50% and 51% and after treatment 35% and 37% for fluticasone and placebo groups respectively (P=0.78 Wilcoxon 2-sided).
Markers
P53
P53 immunohistochemistry showed mainly basal staining concordant with physiological stabilization (possibly as a consequence of cellular stress and DNA damage). In 60 biopsies suprabasal P53 staining was found in small numbers of cells in the superficial layers, without staining of the intermediate layers. Contiguous suprabasal staining of squamous lesions ('true' suprabasal staining) was found in three locations within one subject. Corresponding H&E sections were scored as squamous metaplasia without dysplasia. After six months one of these locations progressed to mild dysplasia, the others remained stable. There was no significant change in the percentage of cells with p53 expression after placebo or fluticasone treatment ( Table 4 Analysis of p53 and KI-67 immunohistochemistry Table 5 Analysis of hTERT expression
KI-67
The proportion of cells staining positive with KI-67 antibody (proliferation index) did not change significantly when comparing the two treatment arms (table 4) .
HTERT
HTERT data before and after treatment could be compared for 245 locations. Mean hTERT was just below 6 per 1000 copies of PBGD at baseline and equal for both treatment arms. The mean change of hTERT expression was equal in the placebo and fluticasone groups (p=0.81 see table 5). 
Discussion
We have performed a randomised, controlled trial of fluticasone, followed by a 1-way crossover from placebo to active treatment, in a high-risk group of smokers. Lung cancer in smokers is a relatively rare occurrence, and when used as the endpoint in a chemoprevention trial, it would take a large cohort and a long follow-up time in order to obtain the number of cases for sufficient statistical power. Therefore, we investigated the chemopreventive potential of fluticasone by examining its effect on squamous precursor lesions of the bronchus. No difference in change of histology between the fluticasone or placebo arms could be detected after a 6 month treatment period. The crossover part of the trial showed the same result. However, because of the absence of a proper control group the value of the crossover data is limited. A similar study has been performed by Lam et al. 13 . Their study showed that inhalation of budesonide (like fluticasone an ICS), has no effect on squamous dysplasia in high risk smokers. In contrast to our results, Lam et al. found that ICS caused a reduction of the percentage of p53 positive cells as well as the number of CT detected nodules.
In a previous study (Breuer et al.) 9 we have shown that suprabasal p53 staining has additional value as a marker in premalignant lesions of the lung. Surprisingly, there was convincing suprabasal staining in lesions of only one subject. Possibly p53 mutation does not occur as often in this population. The subjects in the present study were mainly healthy smokers, whereas many of the patients in the study of Breuer et al. had a history of lung cancer or high grade premalignancy, and lung cancer was the primary outcome. In addition to scoring the lesions with suprabasal staining, the samples were categorized according to the percentage of p53 positive cells (no staining, less than 10% staining, between 10 and 50% and over 50%). As opposed to the results of the study by Lam et al. 13 we found no significant difference between the placebo and fluticasone arms with respect to the percentage of p53 positive cells. The reason for the difference in findings with regard to p53 percentage, may lie in the fact that all study subjects in the study of Lam et al. had bronchial dysplasia, whereas our main inclusion criterion was squamous metaplasia. KI-67 protein is a proliferation marker which cells in any stage of proliferation will express. The ratio of KI-67 positive and negative cells, the proliferation index, is used as a measure of the speed of turnover, which is higher in (pre-) malignant lesions. Smoking causes an elevated proliferative index regardless of the presence of premalignant lesions 14 . The change in KI-67 percentage did not show a significant difference between the two treatment arms. Telomerase activation is a crucial step in development of most tumors. HTERT is one of its components and the rate limiting enzyme 15 , and increased expression was found in 33 out of 38 squamous cell carcinomas in a recent study 16 . Elevated expression in bronchial epithelium was found to be predictive of malignant transformation in several recent retrospective series including our own 10, 17, 18 . We found no significant difference in the change of mean hTERT level between the placebo and fluticasone groups.
Corticosteroids were previously proven effective in reducing the number of lung tumors in A/J mice and rats exposed to cigarette smoke. In a study by Yao et al. 19 the expression profile of mouse lung tumors treated with budesonide was analysed by microarray. The authors concluded that budesonide affected mouse lung tumorigenesis through modulation of the Bcl-2 and caspase-2 regulated apoptosis pathways as well as the Mad2/3 regulated mitotic checkpoint. As Lam et al. 13 speculated, the explanation for the discrepancy between the promising results of trials of ICS in rodents and the lack of effect in humans may lie in the fact that in the rodent lung carcinogenesis model the tumors that develop are all classified as adenocarcinomas and their precursor lesions as adenomas. Since the carcinomas that develop from bronchial epithelium in the large bronchi of humans are squamous carcinomas, the mouse model may not be appropriate for investigating central bronchial carcinogenesis. The reduction in CT detected nodules in the budesonide study 13 could be indicative of an effect on adenomatous precursor lesions, similar to the lesions that develop in the mouse model. We conclude that ICS do not influence squamous bronchial lesions. A possible effect on peripheral adenomatous lesions found in a previous study warrants further investigation.
